 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2020 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS Merus, the Company, we, or our, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and TriclonicsTM, today announced that preclinical data from its MCLA-145 program will be presented at the Society for Immunotherapy of Cancer SITC annual meeting being held virtually on November 1015, 2020. 